0001209191-19-031531.txt : 20190520 0001209191-19-031531.hdr.sgml : 20190520 20190520183631 ACCESSION NUMBER: 0001209191-19-031531 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20190516 FILED AS OF DATE: 20190520 DATE AS OF CHANGE: 20190520 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Bozigian Haig P. CENTRAL INDEX KEY: 0001423837 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-22705 FILM NUMBER: 19840376 MAIL ADDRESS: STREET 1: 12790 EL CAMINO REAL CITY: SAN DIEGO STATE: CA ZIP: 92130 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: NEUROCRINE BIOSCIENCES INC CENTRAL INDEX KEY: 0000914475 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 330525145 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 12780 EL CAMINO REAL CITY: SAN DIEGO STATE: CA ZIP: 92130 BUSINESS PHONE: (858) 617-7600 MAIL ADDRESS: STREET 1: 12780 EL CAMINO REAL CITY: SAN DIEGO STATE: CA ZIP: 92130 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2019-05-16 0 0000914475 NEUROCRINE BIOSCIENCES INC NBIX 0001423837 Bozigian Haig P. 12780 EL CAMINO REAL SAN DIEGO CA 92130 0 1 0 0 Chief Development Officer Common Stock 2019-05-16 4 M 0 22439 35.99 A 164415 D Common Stock 2019-05-16 4 S 0 22439 80.128 D 141976 D Common Stock 2019-05-16 4 M 0 9121 5.76 A 151097 D Common Stock 2019-05-16 4 S 0 9121 80.128 D 141976 D Common Stock 2019-05-16 4 M 0 34376 8.65 A 176352 D Common Stock 2019-05-16 4 S 0 34376 80.128 D 141976 D Common Stock 2019-05-16 4 M 0 731 19.59 A 142707 D Common Stock 2019-05-16 4 S 0 731 80.128 D 141976 D Non-Qualified Stock Option 35.99 2019-05-16 4 M 0 22439 35.99 D 2026-02-05 Common Stock 22439 9094 D Non-Qualified Stock Option 5.76 2019-05-16 4 M 0 9121 5.76 D 2021-08-25 Common Stock 9121 0 D Non-Qualified Stock Option 8.65 2019-05-16 4 M 0 34376 8.65 D 2023-01-10 Common Stock 34376 0 D Non-Qualified Stock Option 19.59 2019-05-16 4 M 0 731 19.59 D 2024-01-16 Common Stock 731 57354 D The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 2 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $80.00 to $80.67. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Option granted February 05, 2016 and vests monthly over four years. Option granted August 25, 2011 and vested monthly over four years. Option granted January 10, 2013 and vested monthly over four years. Option granted January 16, 2014 and vested monthly over four years. /s/ Darin Lippoldt, Attorney-in-Fact 2019-05-20